Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744562 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
A Phase 1 study, sponsored by OncoMed Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00744562 is a Phase 1 study that has completed, run by OncoMed Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT00744562, a Phase 1 study, has completed, sponsored by OncoMed Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
A phase 1 open-label dose escalation study of OMP-21M18 in subjects with previously treated solid tumour for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit.
Interventions
- DRUG OMP-21M18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00744562
The ClinicalTrials.gov registry entry for NCT00744562 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OMP-21M18 is the first listed.
NCT00744562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00744562 about?
NCT00744562 is a clinical study titled "A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors". A phase 1 open-label dose escalation study of OMP-21M18 in subjects with previously treated solid tumour for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit.
What is the current status of trial NCT00744562?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2008-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00744562?
The interventions under investigation include: OMP-21M18 (DRUG).
Who is sponsoring clinical trial NCT00744562?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.